Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PF-06266047 in Healthy Adults
NCT02539550Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Placebo with PF-06266047 (2 arms). Primary endpoints: Number of participants with Adverse Events (AEs), Number of subjects with standard safety laboratory test results of potential clinical significance and 3 more. Started Aug 2015; status: completed.
02
Drugs
PF-06266047
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02539550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539550.